Business
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease
About this update from Inmune Bio Inc.
[{"type":"text","content":"100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease\n Study supports INmune Bio’s approach to treating inflammation as a common mechanism in neurologic disease Accompanying Key Opinion Leader webinar to be hosted on September 29, 2020 to discuss the role of neuroinflammation in treatment resistant depression LA JOLLA, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced it has received a $2.9 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), of which (subject to the terms of the grant), the Company will receive $739,739 this year, $1,210,682 next year with the balance to be received in 2022. The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. The study, entitled, “Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression,” will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. “Treatment resistant depression is a major problem affecting more than seven million patients in the U.S. alone,” said CJ Barnum Ph.D., head of neurosciences at INmune Bio. “This grant is a collaboration with two highly-regarded thought leaders in this difficult to treat condition: Professor Andrew H. Miller, M.D. and Associate Professor Jennifer Felger, Ph.D., both at Emory University. Dr. Miller is the foremost expert in neuroinflammation and depression and published the first study demonstrating that anti-TNF treatment could improve depressive symptoms in patients that had high levels of the inflammatory marker C-Reactive Protein (CRP), a biomarker that will be used to select patients in our study. In addition, Dr. Felger discovered that the connection between two regions of the brain, vital for feelings of pleasure and motivation, are lost in depressed patients with inflammation. Our hypothesis is that XPro1595 will restore this connectivity.” XPro1595 is a selective inhibitor of soluble Tumor Necrosis Facto...